SD-06
CAS No. 271576-80-8
SD-06( SD 06 | SD06 )
Catalog No. M13829 CAS No. 271576-80-8
SD-06 is a p38 MAP kinase inhibitor, inhibits p38α with IC50 of 170 nM and inhibits LPS-stimulated TNF-release in rats.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 56 | In Stock |
|
| 2MG | 30 | In Stock |
|
| 5MG | 50 | In Stock |
|
| 10MG | 79 | In Stock |
|
| 25MG | 141 | In Stock |
|
| 50MG | 221 | In Stock |
|
| 100MG | 330 | In Stock |
|
| 200MG | 461 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSD-06
-
NoteResearch use only, not for human use.
-
Brief DescriptionSD-06 is a p38 MAP kinase inhibitor, inhibits p38α with IC50 of 170 nM and inhibits LPS-stimulated TNF-release in rats.
-
DescriptionSD-06 is a p38 MAP kinase inhibitor, inhibits p38α with IC50 of 170 nM and inhibits LPS-stimulated TNF-release in rats ((83% inhibition at 1mg/kg, po).
-
In VitroSD 0006 clearly inhibits p38α as shown by the dose-dependent inhibition of phosphorylation of its endogenous Hsp27 substrate.
-
In VivoSD 0006 (0-30 mg/kg) may be an effective alternative to steroids and biologics for RA therapy.SD0006 (3.75, 7.5 and 15 mg/kg; p.o.; b.i.d.) is highly effective in attenuating SCW-induced inflammation as shown by the dose-dependent inhibition of paw swelling. Animal Model:8- to 12-week-old DBA/1 mice.Dosage:3.75, 7.5 and 15 mg/kg.Administration:Orally twice daily.Result:Inhibited the transcription of several inflammatory mediators to prevent joint swelling and bone destruction and to preserve bone density.
-
SynonymsSD 06 | SD06
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38 MAPK
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number271576-80-8
-
Formula Weight397.8581
-
Molecular FormulaC20H20ClN5O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 29 mg/mL
-
SMILESOCC(N1CCC(C2=C(C3=NC=NC=C3)C(C4=CC=C(Cl)C=C4)=NN2)CC1)=O
-
Chemical NameEthanone, 1-[4-[5-(4-chlorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-piperidinyl]-2-hydroxy-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
SB 202190
SB 202190 (SB202190, SB-202190) is a potent inhibitor p38α and p38β with IC50 of 50 nM and 100 nM respectively.
-
p38α inhibitor 4
p38α inhibitor 4 is a selective MAPK p38α inhibitor, which is used to study diabetes, pain and chronic inflammation.
-
TAK-715
A potent, selective, orally active p38α MAPK inhibitor with IC50 of 7.1 nM.
Cart
sales@molnova.com